In the long human effort to understand why the air we breathe sometimes turns against us, researchers at the American Cancer Society and Emory University have identified eight molecules in human blood that appear to carry the chemical memory of air pollution exposure — present in the body years before lung cancer emerges. The finding does not yet offer a test or a cure, but it traces a biological thread from an environment most people cannot choose to the cancer that claims more American lives than any other. It also illuminates a quiet inequity: the millions who never smoked but breathe pollu
Air Pollution Leaves Blood Signatures Years Before Lung Cancer
Lung cancer kills more people in the United States than any other cancer, with over half of diagnoses occurring in never-smokers or former smokers.
A biological trail connecting an exposure most cannot avoid to the nation's deadliest cancer
Mark
Why does this study matter if there's no test coming from it?
Mimi
Because it maps the biological trail between something most of us breathe every day and the cancer that kills more Americans than any other. Right now, we screen for lung cancer only in smokers. This work suggests there's a real biological mechanism at play in never-smokers too—and that matters for how we think about who needs screening.
Mark
But you said it doesn't prove the molecules cause cancer.
Mimi
Right. It shows they're present in people exposed to pollution who later got cancer. That's different from proving causation. But it does identify which biological pathways might be involved—inflammation, oxidative stress, how the body detoxifies. That's useful for understanding the mechanism, even if we can't use it clinically yet.
Mark
How far away is a real test?
Mimi
Years. Maybe many years. You have to validate it in different populations, establish thresholds, prove that catching it early actually changes outcomes. This is the very beginning of that road, not the end.
Mark
So what should someone who never smoked but lives in a polluted city do right now?
Mimi
Check air quality on bad days and limit outdoor exertion when it's poor. Use air filters indoors if you can. Pay attention to symptoms—persistent cough, shortness of breath, unexplained weight loss. Talk to a doctor about your risk. But there's no screening test to ask for yet.
Mark
Why does the study focus on never-smokers?
Mimi
Because they're invisible in current screening. The guidelines assume smoking history. But air pollution is classified as a carcinogen just like tobacco. More than half of lung cancers happen in people who never smoked or quit long ago. They have real risk but no way to get screened. This research could eventually change that.
Mark
What's the biggest limitation of what they found?
Mimi
They estimated pollution exposure based on where people lived at one point in time. That doesn't capture where you actually spent your days, your job, your indoor air. And the study population came from two research cohorts, not a representative sample of America. So we don't know if these same metabolites would show up the same way in different regions or different groups of people.
The Pulse
- Lung cancer kills more Americans than any other cancer, yet current screening guidelines exclude never-smokers entirely — a gap that leaves millions with no early-detection option despite documented environmental risk.
- Air pollution has carried the same carcinogen classification as tobacco smoke since 2013, yet over half of lung cancer diagnoses occur in people who never smoked or quit years ago, exposing a structural blind spot in public health policy.
- Researchers identified eight blood metabolites tied to long-term particulate matter and ozone exposure, detectable years before diagnosis — suggesting the body records environmental harm in its chemistry long before disease appears.
- The study is observational and cannot prove causation, predict individual risk, or offer any clinical test; the gap between a biomarker association and a validated screening tool spans years of additional research.
- For now, the only actionable guidance remains unchanged: eligible smokers should discuss low-dose CT screening with a clinician, and anyone with persistent respiratory symptoms should seek evaluation regardless of smoking history.
In the long human effort to understand why the air we breathe sometimes turns against us, researchers at the American Cancer Society and Emory University have identified eight molecules in human blood that appear to carry the chemical memory of air pollution exposure — present in the body years before lung cancer emerges. The finding does not yet offer a test or a cure, but it traces a biological thread from an environment most people cannot choose to the cancer that claims more American lives than any other. It also illuminates a quiet inequity: the millions who never smoked but breathe polluted air have no pathway to screening, even as the science increasingly confirms their risk is real.
A research team at the American Cancer Society and Emory University's Rollins School of Public Health has identified eight molecules in human blood that appear to reflect long-term air pollution exposure — and that were present in people who later developed lung cancer, sometimes years before their diagnosis. The findings, published in Nature Communications, emerged from analysis of plasma samples drawn from 1,357 people who had not yet developed cancer at the time of collection.
The researchers screened more than 1,100 blood metabolites and cross-referenced them against estimated air pollution levels at participants' residences. Four molecules showed particularly strong associations with both particulate matter and ozone exposure, traveling biological pathways involving inflammation, oxidative stress, and detoxification — all previously connected to cancer development. Senior author Donghai Liang emphasized that the central discovery was detecting measurable changes in blood chemistry tied to pollution exposure, visible years before any cancer appeared.
The researchers are careful about the limits of their work. This is an observational study: it shows that certain metabolites were present in people who were both exposed to pollution and later developed lung cancer, but it does not prove those molecules cause cancer, nor does it establish that measuring them in any individual would predict their risk. Pollution exposure was estimated from residential location at a single point in time, missing workplace exposures, indoor air quality, and daily movement patterns. The study cohorts also do not represent the full diversity of the American population.
Most critically, no clinical test exists. Translating a biomarker association into a validated screening tool requires years of separate research, and no threshold for individual risk has been established.
What the research does illuminate is a genuine gap in current practice. Lung cancer screening in the United States — low-dose CT scans — is offered only to adults with substantial smoking histories, excluding never-smokers entirely. Yet outdoor air pollution has been classified as a Group 1 human carcinogen since 2013, and more than half of all U.S. lung cancer diagnoses occur in people who never smoked or quit years ago. These individuals carry real risk from an exposure largely outside their control, with no current pathway to early detection.
A biological marker of pollution-related risk could eventually help identify who might benefit from screening. For now, the guidance is unchanged: those who meet smoking history and age criteria should discuss low-dose CT screening with a clinician. Everyone else can monitor local air quality, limit outdoor exertion on high-pollution days, use indoor filtration where possible, and seek medical evaluation for any persistent cough, unexplained weight loss, chest pain, or shortness of breath — regardless of smoking history.
A team of researchers at the American Cancer Society and Emory University's Rollins School of Public Health has identified eight distinct molecules in human blood that signal long-term exposure to air pollution years before lung cancer appears. The discovery, published in Nature Communications, emerged from analysis of plasma samples collected from 1,357 people who had not yet developed cancer. What makes this finding significant is not that it offers a new way to catch the disease early—it does not—but that it traces a biological pathway from an environmental exposure most Americans cannot escape to the nation's deadliest cancer.
The researchers profiled more than 1,100 metabolites in blood samples and cross-referenced them against residential air pollution concentrations at the time each sample was drawn. Four metabolites in particular—gamma-glutamylglutamine, phenylacetylglutamate, N-(2-furoyl)glycine, and 4-vinylguaiacol glucuronide—showed strong associations with both particulate matter and ozone exposure. The biological pathways these molecules travel involve inflammation, oxidative stress, detoxification, and energy metabolism, all of which have been previously linked to cancer development. Donghai Liang, an associate professor of environmental health at Emory and one of the study's senior authors, emphasized that the key finding was detecting measurable changes in the blood metabolome tied to pollution exposure, detectable years before any cancer diagnosis.
But the researchers are careful about what this work does and does not show. This is an observational study, meaning it demonstrates that certain metabolites were present in people who later developed lung cancer and who had been exposed to pollution, but it does not prove those molecules cause cancer. It does not establish that measuring them in any individual person would predict their risk. The pollution exposure itself was estimated based on where people lived at a single point in time, a reasonable approach for studying populations but one that misses where people actually spent their days, what they encountered at work, or the quality of air inside their homes. The study participants came from two research cohorts that do not represent the full diversity of the American population, so whether these same metabolite patterns would appear across different regions, ancestries, and exposure profiles remains unknown.
What matters most is what does not exist: no blood test, no threshold for risk, no evidence that identifying these molecules in a person would change their medical outcomes. Turning a biomarker association into a validated screening tool typically requires years of separate research. The same researchers' earlier work in these same cohorts shows how incremental that path can be.
Yet the research points toward a real gap in current practice. Lung cancer screening in the United States relies on low-dose CT scans offered to adults roughly 50 to 80 years old with substantial smoking histories. That design excludes never-smokers entirely. Since 2013, outdoor air pollution has been classified as a Group 1 human carcinogen—the same category as tobacco smoke—based on review of more than 1,000 studies. Prospective cohort research has found that long-term exposure to particulate matter is associated with lung cancer even among people who never smoked. More than half of all lung cancers in the United States are diagnosed in people who never smoked or who quit years ago. These never-smokers have no pathway to screening under current guidelines, despite carrying real risk from an environmental exposure they cannot fully control.
A biological marker of pollution-related risk could eventually help identify people who would benefit from screening but do not qualify today. Eventually is the operative word. For now, the actionable guidance remains unchanged and unglamorous. People who currently smoke or formerly smoked and meet age and pack-year criteria should discuss low-dose CT screening with a clinician; many insurance plans cover it without cost-sharing. Everyone else can take modest steps: checking local air quality on high-pollution days, limiting outdoor exertion when levels spike, using indoor air filtration where feasible, and avoiding secondhand smoke. Anyone experiencing a persistent cough, coughing up blood, unexplained weight loss, chest pain, or shortness of breath should seek evaluation regardless of smoking history. The researchers continue examining lung cancer metabolomics in these cohorts, but any clinical application would first need to clear years of validation before it could become a tool in a doctor's hands.
Notable Quotes
The notable element was identifying measurable changes in human blood metabolome associated with air pollution exposure years before lung cancer was diagnosed— Donghai Liang, associate professor of environmental health at Emory University
Want the full story?
Read the original at Medical Daily ↗
Health & Medicine